Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 22 | -1.40 Increased by +36.36% | 0.20 Decreased by -4.00 K% |
| Aug 9, 22 | 1.80 | -2.60 Increased by +65.09% |
| May 16, 22 | 1.00 | -2.60 Increased by +53.25% |
| Mar 31, 22 | 1.00 | -2.60 Increased by +53.25% |
| Nov 15, 21 | -2.20 | -2.40 Increased by +3.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.73 M Decreased by -169.50% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -21.74 M Decreased by -2.30 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -38.92 M Decreased by -312.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | 10.40 M Increased by +144.33% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | 6.81 M Increased by +142.03% | Increased by +N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | 989.81 K Increased by +152.62% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | 18.30 M Increased by +646.28% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -23.46 M Decreased by -8.87 K% | Decreased by N/A% Decreased by N/A% |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.